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Abstract
Background: Sustained agonist-promoted ubiquitination of β-arrestin has been correlated with
increased stability of the GPCR – β-arrestin complex. Moreover, abrogation of β-arrestin
ubiquitination has been reported to inhibit receptor internalization with minimal effects on
receptor degradation.
Results: Herein we report that agonist activation of M1 mAChRs produces a sustained β-arrestin
ubiquitination but no stable co-localization with β-arrestin. In contrast, sustained ubiquitination of
β-arrestin by activation of M2 mAChRs does result in stable co-localization between the M2 mAChR
and β-arrestin. Internalization of receptors was unaffected by proteasome inhibitors, but down-
regulation was significantly reduced, suggesting a role for the ubiquitination machinery in promoting
down-regulation of the receptors. Given the ubiquitination status of β-arrestin following agonist
treatment, we sought to determine the effects of β-arrestin ubiquitination on M1 and M2 mAChR
down-regulation. A constitutively ubiquitinated β-arrestin 2 chimera in which ubiquitin is fused to
the C-terminus of β-arrestin 2 (YFP-β-arrestin 2-Ub) significantly increased agonist-promoted
down-regulation of both M1 and M2 mAChRs, with the effect substantially higher on the M2 mAChR.
Based on this observation, we were interested in examining the effects of disruption of potential
ubiquitination sites in the β-arrestin sequence on receptor down-regulation. Agonist-promoted
internalization of the M2 mAChR was not affected by expression of β-arrestin lysine mutants lacking
putative ubiquitination sites, β-arrestin 2K18R, K107R, K108R, K207R, K296R, while down-regulation and
stable co-localiztion of the receptor with this β-arrestin lysine mutant were significantly reduced.
Interestingly, expression of β-arrestin 2K18R, K107R, K108R, K207R, K296R increased the agonist-promoted
down-regulation of the M1 mAChR but did not result in a stable co-localiztion of the receptor with
this β-arrestin lysine mutant.
Conclusion: These findings indicate that ubiquitination of β-arrestin has a distinct role in the
differential trafficking and degradation of M1 and M2 mAChRs.
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Background
There are five subtypes of muscarinic acetylcholine recep-
tors (M1 – M5 mAChR) with distinct yet overlapping tissue
distributions. Muscarinic receptors regulate a variety of
physiological responses ranging from cardiac homeostasis
to cholinergic signaling in the brain [1]. A common fea-
ture of mAChRs, and in fact all GPCRs, is that both their
expression and activation are tightly regulated. Agonist-
promoted trafficking of mAChRs, and most other GPCRs
can be broken down into five distinct phases: agonist-
binding promotes G protein dissociation (I) from the
receptor which allows phosphorylation of specific serine
and threonine residues (II) on internal loops of the recep-
tor by G protein receptor kinases (GRKs). This phosphor-
ylation allows the binding of β-arrestins (III) which
promotes homologous desensitization and subsequent
internalization of the receptor into clathrin coated pits.
Following internalization, the receptor can either be
dephosphorylated and recycled (IV) to the cell surface or
targeted for degradation (V) in proteasomes or lysosomes
[1].
β-arrestins have emerged as a central control point in the
trafficking of nearly all GPCRs [2]. In addition to mediat-
ing desensitization of GPCRs, β-arrestin also participates
in clathrin-dependent endocytosis of activated receptors
by directly interacting with clathrin and the clathrin-asso-
ciated adaptor AP-2 [3,4]. Once internalized, β-arrestins
are involved in regulation of post-endocytotic trafficking
and recently have been shown to function as scaffolding
proteins interacting with cellular trafficking machinery
[2,5].
Initial reports examining the role of β-arrestin, clathrin
and dynamin indicated that agonist-promoted internali-
zation of the M2 mAChR proceeded via both arrestin-
dependent and -independent pathways [6,7]. Later work,
however, indicated the essential role of β-arrestin in M2
mAChR internalization, and suggested that all M2 mAChR
internalization, like other mAChR subtypes, is dynamin-
dependent [8,9].
Two classes of GPCRs have been identified with respect to
kinetics of receptor recycling and interaction with β-
arrestins. Class A receptors, such as the β2 adrenergic
(β2AR), dopamine D1A and endothelin 1A receptors recy-
cle rapidly and dissociate from β-arrestin prior to receptor
internalization. Class B receptors, such as the vasopressin
2 (V2R), angiotensin 1a and neurotensin 1 receptors, recy-
cle slowly and internalize in a stable association with β-
arrestin [10,11]. Recently, it has become clear that the
classification of receptors as A or B directly correlates with
patterns of β-arrestin ubiquitination and deubiquitina-
tion [12]. Stimulation of Class A β2ARs leads to transient
ubiquitination of β-arrestin with deubiquitination occur-
ring shortly (minutes) after internalization [12]. In con-
trast, stimulation of Class B V2Rs leads to a stable
ubiquitination of β-arrestin [12].
Ubiquitination of proteins is a signal for degradation that
leads to delivery to and degradation of proteins in the 26S
proteasome [13]. There are a number of examples where
ubiquitination has been shown to be involved in the reg-
ulation of GPCRs, including the opiod receptors [14],
yeast pheromone receptor [15], human immunodefi-
ciency virus co-receptor CXCR4 [16], and β2 ARs [17].
Class A receptors, which do not internalize with β-arres-
tin, display a pattern of transient β-arrestin ubiquitina-
tion. Class B receptors, on the other hand, do internalize
with β-arrestin, and display a sustained β-arrestin ubiqui-
tination pattern [12]. Shenoy et al. [17] showed that ago-
nist stimulation led to the ubiquitination of both β-
arrestin and the β2 AR. Their data suggested that it was the
ubiquitination of β-arrestin that was involved in the ini-
tial receptor internalization step whereas ubiquitination
of the receptor itself was required for subsequent receptor
degradation.
In the present study, we wanted to address several ques-
tions regarding the role of β-arrestin ubiquitination in the
agonist-promoted down-regulation of mAChRs. First we
wanted to determine if there was a role for β-arrestin ubiq-
uitination in receptor down-regulation. Collectively, our
data support a role for β-arrestin in differential targeting
of mAChRs towards down-regulation. In addition, the
data indicate that this differential targeting may be con-
trolled by preferential interaction of mAChR subtypes
with the different β-arrestin subtypes which in turn may
be mediated by specific patterns of β-arrestin ubiquitina-
tion.
Results
For a number of years there has been some controversy as
to the role of β-arrestin in M2 mAChR specific internaliza-
tion and down-regulation. Our recent publication [9]
established the essential role of β-arrestin in the internal-
ization of the M2 mAChR. The current study is a follow up
which not only addresses the role of β-arrestin in agonist-
promoted mAChR down-regulation, but also indicates a
differential role for β-arrestin in M1 versus M2 mAChR
down-regulation. As in the previous study, we performed
our down-regulation experiments in mouse embryonic
fibroblasts (MEFs) derived from β-arrestin 1/2 double
knockout mice (MEF KO1/2) [18]. Experiments per-
formed using this cell line offer a significant advantage
over previous studies of the role of β-arrestin in GPCR
internalization and down-regulation that used dominant-
negative or knockdown strategies because they avoid any
possible complications that could arise from the presenceJournal of Molecular Signaling 2008, 3:20 http://www.jmolecularsignaling.com/content/3/1/20
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of low levels of endogenous arrestin proteins. These cells
have been characterized to confirm the absence of mAChR
expression using both PCR and radioligand binding
assays [9].
To determine whether or not MEF cells could be used in
the current study, we performed agonist-promoted down-
regulation time courses for both the M1 and M2 mAChR
subtypes. Total receptor numbers were measured using
the non-selective membrane permeable muscarinic antag-
onist quinuclidinyl benzilate (QNB), which binds to both
surface and intracellular pools of mAChR. Wild-type MEF
cells that were transfected with either eGFP-M1 mAChR or
HA-M2  mAChR resulted in similar expression levels
(~4000 fmol/mg). After 24 hr, cells were treated with 1
mM carbachol for the indicated time. Maximal down-reg-
ulation of the M2 mAChR occurred after 6 hr of stimula-
tion (Figure 1). In contrast, maximal down-regulation of
the M1 subtype did not occur until after 12 hr of carbachol
stimulation. In addition, M2 mAChRs were maximally
decreased by only 22% while the M1  subtype was
decreased by 55%. These results demonstrate that exoge-
nously expressed M1 and M2 mAChRs undergo agonist-
promoted down-regulation in MEFwt cells. The different
time course and extent of down-regulation suggest the
possibility that down-regulation of the two subtypes may
involve distinct pathways. Despite the fact that M2
mAChRs were maximally down-regulated by 6 hr of stim-
ulation, subsequent single time point experiments used
the 12 hr time point so that the M1 and M2 subtype exper-
iments would be compared at a standardized time point.
Several recent studies have reported that mAChR down-
regulation occurs independently of agonist-promoted
internalization [19-21]. Recently, we demonstrated that
agonist-promoted internalization of M2 mAChRs in MEF
cells was β-arrestin dependent [9]. To examine whether or
not agonist-promoted down-regulation of M1  and M2
mAChRs is β-arrestin dependent, we performed down-
regulation studies in MEF β-arrestin double knockout cells
transiently expressing either M1  or M2  mAChRs. MEF
KO1/2 cells were transfected with eGFP-M1 mAChR or
HA-M2 mAChR and either FLAG-β-arrestin 1 or 2. After 24
hr, cells were treated with 1 mM carbachol for 12 hr. In the
absence of exogenous β-arrestin, there was no down-regu-
lation in response to agonist stimulation in the double
knockout cell line (Figure 2A–D). Expression of either β-
arrestin 1 or β-arrestin 2, however, rescued down-regula-
tion of both receptor subtypes in response to agonist (Fig-
ure 2A – D). These results demonstrate that agonist-
promoted down-regulation of M1 and M2 mAChRs is β-
arrestin dependent.
Recent studies have demonstrated that agonist stimula-
tion of GPCRs results in ubiquitination of β-arrestin 2
[12]. This group demonstrated receptor specific agonist-
promoted ubiquitination of β-arrestin 2 that was either
transient (peaked at 1 min of agonist stimulation) or sta-
ble (still present after 15 min of agonist stimulation) [12].
We performed experiments in order to determine if ago-
nist stimulation of M1 or M2 mAChRs promoted the ubiq-
uitination of β-arrestin and if so, examine whether the
observed ubiquitination was transient or stable. MEF
KO1/2 cells were transfected with FLAG-β-arrestin 2 and
eGFP-M1 or HA-M2 mAChR and treated with carbachol for
0, 1, 3, 15 and 30 min. Stimulation of M1 and M2 mAChRs
significantly increased ubiquitination of β-arrestin 2 (Fig-
ure 3). This increase is clearly visible at both the 15 and 30
min time point for both mAChR subtypes. These results
demonstrate that stimulation of M1 or M2 mAChRs pro-
motes a stable ubiquitination of β-arrestin 2.
Having established that β-arrestin is required for mAChR
down-regulation and that muscarinic stimulation leads to
the ubiquitination of β-arrestin, we wanted to examine if
there was a direct role for β-arrestin ubiquitination in
receptor down-regulation. Since ubiquitination is known
to serve as a signal for protein degradation [13] we were
interested in determining whether disruption of the ubiq-
uitin/proteasome pathway would affect the agonist-pro-
Time-course of agonist-promoted down-regulation of  mAChRs in MEF Figure 1
Time-course of agonist-promoted down-regulation 
of mAChRs in MEF. MEF wt cells were transfected with 
eGFP-M1 (r) or HA-M2 (n) mAChR. 24 hr following transfec-
tion, cells were treated with 1 mM carbachol for the indi-
cated time. Down-regulation was determined using [3H]-
QNB binding (fmol/mg protein) in crude membranes as 
described in methods. The M1 mAChR displays nearly three-
fold the down-regulation of the M2 subtype over the same 
time course. Data are expressed as percent down-regulation 
compared to t = 0 control and are presented as mean ± 
standard error of the mean for three independent experi-
ments with duplicate data points. Total mAChR expressed 
(fmol/mg) at t = 0 was 4000 for both M1 and M2 mAChRs.
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moted down-regulation of the mAChRs. To confirm that
β-arrestin 2 promotes down-regulation via a ubiquitin
dependent pathway, we examined agonist-promoted
down-regulation of the M2 mAChR in the presence of the
proteosomal inhibitor lactacystin (impairs ubiquitin recy-
cling). MEFwt cells were transfected with HA-M2 mAChR
and after 24 hr cells were incubated for 20 min with or
without 10 μM lactacystin prior to treatment with 1 mM
carbachol for 4 hr. Lactacystin was able to completely
block agonist-promoted down-regulation (Figure 4) sug-
gesting that the ubiquitination machinery has a role in
mediating agonist-promoted down-regulation of
mAChRs.
To determine whether or not the effects of lactacystin were
occurring at the level of receptor internalization, we exam-
ined the effect of lactacystin on the agonist-promoted
internalization of mAChRs using the membrane imper-
meable muscarinic antagonist N-methylscopolamine
(NMS). MEFwt cells were transfected with HA-M2 mAChR,
and after 24 hr cells were incubated for 20 min in the
absence or presence of 10 μM lactacystin prior to treat-
ment with 1 mM carbachol for 30 min. Pretreatment with
inhibitor had no effect on agonist-promoted internaliza-
tion (Figure 5). These results indicate that agonist-pro-
moted down-regulation of mAChRs involves receptor β-
arrestin ubiquitination.
Rescue of mAChR down-regulation in MEF KO1/2 with β-arrestin 1 or 2 Figure 2
Rescue of mAChR down-regulation in MEF KO1/2 with β-arrestin 1 or 2. MEF KO1/2 cells were transfected with 
eGFP-M1 mAChR (A-B) or HA-M2 mAChR (C-D) and either FLAG-β-arrestin 1 (top) or 2 (bottom). 24 hr following trans-
fection, cells were treated with 1 mM carbachol for 12 hr. Down-regulation was determined using [3H]-QNB binding (fmol/mg 
protein) in crude membranes as described in methods. No down-regulation occurs in the absence of β-arrestin and either iso-
form (β-arrestin 1 or 2) rescues both constitutive and agonist-promoted down-regulation. Data are expressed as percent of 
[3H]-QNB bound (fmol/mg total protein) compared to untreated, no β-arrestin control and are presented as mean ± standard 
error of the mean from three independent experiments with duplicate data points. Statistical analysis was performed using a 
paired t-test. *: p ≤  0.05 versus the untreated, no β-arrestin control. Total M1 mAChR expressed (fmol/mg) at t = 0 was 400 – 
900 (M1) and 1000 – 2000 (M2) for both the β-arrestin 1 and β-arrestin 2 rescue experiments.
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To examine the consequences of β-arrestin ubiquitination
on receptor down-regulation, we expressed a yellow fluo-
rescent protein-tagged β-arrestin 2-ubiquitin chimera that
cannot be deubiquitinated by cellular deubiquitinases
(YFP-β-arrestin 2-Ub) [12]. MEF KO1/2 cells were trans-
fected with eGFP-M1 or HA-M2 mAChR and either FLAG-
β-arrestin 2 or YFP-β-arrestin 2-Ub. After 24 hr, cells were
treated with 1 mM carbachol for 12 hr. There was a 40%
agonist-promoted down-regulation of the M1 mAChR by
β-arrestin 2 alone which increased to 70% in the presence
of β-arrestin 2-Ub (Figure 6). These values were 62 and
95%, respectively, for the M2 subtype (Figure7). β-arrestin
2-Ub also increased the constitutive receptor down-regu-
lation, and again the effect was much larger for the M2
(90%) vs M1 (50%) subtype (Figure 6A and 6B). It is clear
from these data that ubiquitination enhanced the ability
of β-arrestin 2 to mediate both constitutive and agonist-
promoted down-regulation of both the M1  and M2
mAChRs.
Having demonstrated a role for ubiquitin in agonist-pro-
moted mAChR degradation, we were interested in the
effects of disrupting β-arrestin 2 ubiquitination on recep-
tor down-regulation. Several lysine residues on β-arrestin
are known to be sites of ubiquitination [22]. To further
confirm the essential role of ubiquitination in agonist-
promoted down-regulation, we examined the ability of
specific β-arrestin 2 lysine mutants to mediate agonist-
promoted down-regulation of the M1 and M2 mAChR.
MEF KO1/2 cells were transfected with eGFP-M1 or HA-M2
mAChR and either empty vector (control), FLAG-β-arres-
tin 2 (wild-type), FLAG-β-arrestin 2K18R, K107R, K108R, K207R,
K296R or FLAG-β-arrestin 2K11R, K12R. After 24 hr, cells were
treated with 1 mM carbachol for 12 hr. As shown previ-
ously, there was no down-regulation in the control cells in
the absence of β-arrestin 2 (Figure 7). All three β-arrestin
2 constructs were able to rescue agonist-promoted down-
regulation of the M1 subtype. We also noted a large consti-
tutive effect on down-regulation with both mutant β-
arrestins. In contrast, for the M2 subtype only wild-type β-
arrestin 2 (24%) and β-arrestin 2K11R, K12R (27%) were able
to rescue agonist-promoted down-regulation (Figure 7).
β-arrestin 2K18R, K107R, K108R, K207R, K296R, had lost the ability
Agonist treatment promotes ubiquitination of β-arrestin 2 in MEF KO1/2 cells expressing the mAChRs and β-arrestin 2 Figure 3
Agonist treatment promotes ubiquitination of β-arrestin 2 in MEF KO1/2 cells expressing the mAChRs and β-
arrestin 2. MEF KO1/2 cells transfected with FLAG-β-arrestin 2 and either eGFP-M1 or HA-M2 mAChR. 24 hr following trans-
fection, cells were treated with 1 mM carbachol for the indicated times. Top panel: cells were lysed and immunoprecipitated 
(IP) with anti-FLAG MAb and blotted (IB) with anti-ubiquitin-MAb. There was an increase in ubiquitination of β-arrestin 2 with 
increasing exposure to 1 mM carbachol. Each blot is representative of two independent experiments. Bottom panel: lysates 
blotted with anti-FLAG MAb to demonstrate β-arrestin 2 expression levels.
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to rescue agonist-promoted down-regulation of the M2
mAChR (Figure 7).
Since it was possible that the effect of β-arrestin 2K18R,
K107R, K108R, K207R, K296R on M2  mAChR down-regulation
seen in the previous experiment was actually occurring at
the receptor internalization step, we performed receptor
internalization experiments with [3H]-NMS. Transfections
were identical to the previous experiment. After 24 hr,
cells were treated with 1 mM carbachol for 1 hr. All β-
arrestin 2 constructs (wild-type or lysine mutants) were
able to rescue agonist-promoted internalization of M2
mAChRs in MEF KO1/2 (Figure 8).
Since  β-arrestin 2K18R, K107R, K108R, K207R, K296R not only
appears to interfere with the agonist promoted down-reg-
ulation of the M2 mAChR but also increased the constitu-
tive down-regulation of the M1 mAChR we examined the
ability of this mutant to co-localize with the M1/M2
mAChR compared to wt and β-arrestin 2K11R, K12R follow-
ing agonist stimulation. MEF KO1/2 were plated on cover
slips in 6-well plates. 24 hrs after transfection with eGFP-
M1 mAChR or HA-M2 mAChR and FLAG tagged β-arrestin
(wt or lysine mutants) cells were treated for 30 min or 12
hrs with 1 mM carbachol. Cells were fixed and processed
for indirect immunofluorescence as described in meth-
ods. After 30 minutes of agonist exposure there is clear
overlap of the M2 mAChR receptor and β-arrestin signal
signified by the yellow puncta (Figure 9) for the wt and β-
arrestin 2K11, K12R. This overlap is absent with β-arrestin
2K18R, K107R, K108R, K207R, K296R which indicates a disrupted or
impaired interaction between this β-arrestin mutant and
the M2 mAChR. Surprisingly, despite our previous obser-
vation of the effects of β-arrestin 2K18R, K107R, K108R, K207R,
K296R on constitutive M1 down-regulation, no co-localiza-
tion was observed between β-arrestin and the M1 mAChR
(Figure 10).
Finally we used immunocytochemistry with the lyso-
somal marker LAMP-1 to examine the effects of the β-
arrestin 2K18R, K107R, K108R, K207R, K296R mutant on mAChR
lysosomal targeting down-regulation. MEF KO1/2 were
transfected with HA-M2 mAChR and either empty vector
(control), FLAG-β-arrestin 2 (wild-type), FLAG-β-arrestin
The proteosomal inhibitor lactacystin inhibits the β-arrestin  2 mediated agonist-promoted down-regulation of the M2  mAChR in MEFwt Figure 4
The proteosomal inhibitor lactacystin inhibits the β-
arrestin 2 mediated agonist-promoted down-regula-
tion of the M2 mAChR in MEFwt. MEFwt cells were 
transfected with HA-M2 mAChR and, after 24 hr cells were 
incubated for 20 min with or without 10 μM lactacystin then 
treated with 1 mM carbachol for 4 hr. Lactacystin inhibits the 
β-arrestin 2 mediated down-regulation of the M2 mAChR 
receptor in response to agonist. Down-regulation was deter-
mined using [3H]-QNB binding in crude membranes as 
described in methods. Data are expressed as [3H]-QNB 
bound (fmol/mg total protein) and are presented as mean ± 
standard deviation from three independent experiments with 
duplicate data points. Statistical analysis was performed using 
a paired t-test, ** indicates p ≤  0.001 (compared to paired 
untreated control), ns indicates not significant.
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The proteosomal inhibitor lactacystin does not affect agonist- promoted down-regulation internalization of the M2 mAChR  in MEFwt Figure 5
The proteosomal inhibitor lactacystin does not affect 
agonist-promoted down-regulation internalization of 
the M2 mAChR in MEFwt. MEFwt cells were transfected 
with HA-M2 mAChR and, after 24 hr cells were incubated for 
20 min with or without 10 μM lactacystin then treated with 1 
mM carbachol for 30 min. Lactacystin has no effect on the 
internalization of the M2 mAChR receptor in response to 
agonist. Internalization was determined using [3H]-NMS bind-
ing in whole cells as described in methods. Data are [3H]-
NMS bound per well (plated at 1 × 105 cells) and are pre-
sented as mean ± standard deviation from three independent 
experiments with duplicate data points. Statistical analysis 
was performed using a paired t-test, * indicates p ≤  0.05; 
(compared to paired untreated control), ns indicates not sig-
nificant.
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2K11R, K12R or FLAGβ-arrestin 2K18R, K107R, K108R, K207R, K296R.
After 24 hr, cells were treated with 1 mM carbachol for 6
hr. There was significant co-localization of the receptor
with LAMP-1 in the presence of wild-type β-arrestin 2 or
β-arrestin 2K11R, K12R (Figure 11). It is clear, however, that
β-arrestin 2K18R, K107R, K108R, K207R, K296R shows reduced co-
localization of the M2 mAChR with LAMP (Figure 11).
Collectively, these data indicate that the agonist-pro-
moted down-regulation of the M1  and M2  mAChRs
involves differential sorting of the receptor by ubiquiti-
nated β-arrestin.
Discussion
Our recent work established the essential role of β-arrestin
in the internalization of the M2 mAChR [9]. The present
study extends the observations of previous work and dem-
onstrates that the agonist-promoted down-regulation of
M1 and M2 mAChRs is β-arrestin dependent, and that the
ubiquitination pattern of β-arrestin has a critical role in
the differential down-regulation for M1 vs M2 mAChRs.
It has been previously established in a variety of cell lines
that a prolonged activation of M1 or M2 mAChRs induces
receptor down-regulation. In agreement with these find-
ings, long-term stimulation of M1 or M2 mAChRs induced
receptor down-regulation with the M1 mAChR showing
significantly more down-regulation than M2 subtype. This
observation suggests that the two subtypes are differen-
tially regulated by endogenous β-arrestins. No down-reg-
ulation of either mAChR subtype occurred in the absence
of β-arrestin and either β-arrestin subtype was able to res-
cue receptor down-regulation.
The observations of Shenoy and co-workers suggest that
the ubiquitination of β-arrestin is a critical control point
in the trafficking of different classes of GPCRs [12,17,22].
The time course of ubiquitination of β-arrestin 2 in
response to muscarinic stimulation in MEF KO1/2 cells
transiently expressing the M1 or M2 mAChRs was slow in
onset and stable over time. This observation suggests that
both M1 and M2 mAChRs display a Class B β-arrestin ubiq-
uitination pattern despite the fact that the M1 mAChR is
known to recycle rapidly compared to M2 [23], and does
not show a stable endocytotic co-localization with β-arres-
tin 2 [9] – both characteristics of Class A GPCRs. This
observation suggests that there is some flexibility in the
Class A vs B distinction. This same flexibility has been
observed in the categorization of somatostatin receptor
subtypes [24].
To confirm that agonist-promoted down-regulation of
mAChRs was ubiquitin-dependent we performed inter-
nalization/down-regulation experiments in the presence
of the proteosomal inhibitor lactacystin. Lactacystin is a
specific inhibitor of the 26S proteasome that functions by
covalently modifying the active site and inhibiting the
enzymatic activity of the proteasome [13]. This inhibition
of the enzyme would inhibit recycling and thus deplete
the available ubiquitin. Lactacystin was able to completely
block agonist-promoted down-regulation with no effect
on agonist-promoted internalization. These results sug-
gested that the availability of free ubiquitin has a role in
agonist-promoted down-regulation of the mAChRs. This
effect is most likely due to effects on ubiquitin-dependent
lysosomal sorting as evidenced by a later experiment that
demonstrated the co-localization of the agonist-internal-
ized M2 mAChR with the lysosomal membrane protein
LAMP-1.
Expression of a chimeric ubiquitinated form of β-arrestin 2  enhances the agonist-promoted down-regulation of M1 and  M2 mAChRs in MEF KO1/2 Figure 6
Expression of a chimeric ubiquitinated form of β-
arrestin 2 enhances the agonist-promoted down-reg-
ulation of M1 and M2 mAChRs in MEF KO1/2. MEF 
KO1/2 cells were transfected with eGFP-M1 (A) or HA-M2 
(B) mAChRs and either no β-arrestin, FLAG-β-arrestin 2 or 
YFP-β-arrestin 2-Ub. 24 hr following transfection, cells were 
treated with 1 mM carbachol for 12 hr. Down-regulation was 
determined using [3H]-QNB binding (fmol/mg protein) in 
crude membranes as described in methods. Expression of 
the constitutively ubiquitinated form of β-arrestin (β-arrestin 
2-Ub) had a greater effect on down-regulation of the M2 
mAChR compared to the M1 subtype. Data are expressed as 
percent of [3H]-QNB bound compared to the untreated 
control with no β-arrestin and are presented as mean ± 
standard deviation from two independent experiments with 
duplicate data points. Statistical analysis was performed using 
a repeated measures ANOVA with Bonferroni post test; * 
indicates p ≤  0.05 and ** indicates p ≤  0.001 (compared to 
untreated, no β-arrestin control), ns indicates not significant. 
Total mAChR expressed (fmol/mg) in the absence of β-arres-
tin was 1000 – 2000 for both receptor subtypes.
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Having established that β-arrestin is ubiquitinated via
mAChR activation, we then examined whether the ubiq-
uitination of β-arrestin enhances its ability to mediate
agonist-promoted down-regulation. M1  mAChR levels
were reduced and M2  levels were nearly completely
ablated in the presence of β-arrestin 2-Ub compared to
wild-type β-arrestin. The effect was seen on both constitu-
tive and agonist promoted down-regulation.
In order to examine the role of β-arrestin ubiquitination
in targeting mAChRs toward degradation, we used β-arres-
tin lysine mutants that have been previously shown to
have a role in the endocytotic trafficking of other GPCRs.
The constructs, generated by Shenoy and co-workers, con-
tain mutations of potential ubiquitination sites near the
amino terminus (β-arrestin 2K11R, K12R) and at five other
sites in the protein (β-arrestin 2K18R, K107R, K108R, K207R,
K296R) [22]. We were particularly interested in the possible
differential effects of β-arrestin ubiquitination patterns on
M1 vs M2 down-regulation given the fact that M1 and M2
mAChRs did not fit neatly into the classical Class A vs B
distinction.
Both of the β-arrestin lysine mutants were able to mediate
agonist-promoted down-regulation of the M1 mAChR to
the same extent as wild-type β-arrestin. While our data
clearly indicates an essential role for β-arrestin ubiquitina-
tion in M1 mAChR down-regulation, other lysine residues
than the ones examined must be the targets for the neces-
sary ubiquitination required for targeting the M1 mAChRs
β-arrestin 2K18R, K107R, K108R, K207R, K296Rdifferentially affects down-regulation of M1 and M2 mAChRs in MEF KO1/2 Figure 7
β-arrestin 2K18R, K107R, K108R, K207R, K296Rdifferentially affects down-regulation of M1 and M2 mAChRs in MEF KO1/
2. MEF KO1/2 cells were transfected with eGFP-M1 (A) mAChR or HA-M2 (B) mAChR and either empty vector (control), 
FLAG-β-arrestin 2 (WT), FLAG-β-arrestin 2K18R, K107R, K108R, K207R, K296R or FLAG-β-arrestin 2K11R, K12R. 24 hr after transfection, 
cells were treated with 1 mM carbachol for 12 hr. Down-regulation was determined in crude membranes (fmol/mg protein) as 
described in methods. All β-arrestin 2 constructs were able to mediate agonist-promoted down-regulation of mAChR with the 
exception of the β-arrestin 2K18R, K107R, K108R, K207R, K296R mutant when co-expressed with the M2 mAChR. Data are expressed as 
percent of [3H]-QNB bound (compared to untreated, no β-arrestin control) and presented as mean ± standard deviation from 
three independent experiments with duplicate or quadruplicate data points. Statistical analysis was performed using a repeated 
measures ANOVA with Bonferroni post test; * indicates p ≤  0.05 ** indicates p ≤  0.001 (compared to untreated, no β-arrestin 
control), ns indicates not significant. Total M1 (300–500 fmol/mg) and M2 (1500–2500 fmol/mg) mAChR expressed in the 
absence of β-arrestin constructs was similar.
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toward down-regulation. We did observe increased con-
stitutive down-regulation of the M1 mAChR with both
mutant β-arrestin constructs. It is possible that the pattern
of ubiquitination of these mutant β-arrestins altered the
constitutive targeting of the M1 mAChR toward lysosomal
down-regulation. This observation is one of several in this
study that suggests that the pattern of ubiquitination on β-
arrestin is directly implicated in the downstream targeting
of mAChRs. Previously it has been suggested that the only
role for β-arrestin ubiquitination is to promote the inter-
nalization of GPCRs.
We obtained surprisingly different results with the effects
of the β-arrestin lysine mutants on the agonist-promoted
down-regulation of the M2 mAChR subtype. Mutation of
the two lysine residues in β-arrestin 2K11R, K12R had no
effect on either agonist-promoted internalization or
down-regulation of M2 mAChRs. This result is similar to
those seen with other Class B receptors such as the V2R
and NK1R [22]. The results are different however from
those seen with another Class B receptor, the AT1a recep-
tor. When this receptor was co-expressed with β-arrestin
2K11R, K12R, agonist stimulation resulted in transient asso-
ciation of the receptor with β-arrestin 2, thus converting
the receptor to a Class A type.
In contrast, the β-arrestin 2K18R, K107R, K108R, K207R, K296R
mutant significantly reduced M2  mAChR degradation
with no effect on receptor internalization. These results
are similar to those seen with the Class B V2R, where β-
arrestin 2K18R, K107R, K108R, K207R, K296R was shown to impair
association of V2Rs with β-arrestin 2 on endosomes [22].
The fact that β-arrestin 2K18R, K107R, K108R, K207R, K296R was
able to internalize but not down-regulate the M2 mAChR
suggests that one or more of these lysines has a role in
down-regulation but not internalization for this subtype.
These data suggest a direct role for the ubiquitination state
of β-arrestin in the lysosomal targeting of the M2 mAChR.
Unlike effects observed with the M2 mAChR, β-arrestin
2K18R, K107R, K108R, K207R, K296R was able to mediate down-reg-
ulation of M1 mAChRs. This observation clearly demon-
strates that the role of these lysines in down-regulation is
subtype specific and that a specific pattern of ubiquitina-
tion on β-arrestin can differentially target the two mAChR
subtypes for down-regulation.
Agonist-promoted internalization of M2 mAChR is unaffected  by β-arrestin 2 lysine mutants in MEF KO1/2 Figure 8
Agonist-promoted internalization of M2 mAChR is 
unaffected by β-arrestin 2 lysine mutants in MEF 
KO1/2. MEF KO1/2 cells were transfected with HA-M2 
mAChR and either empty vector (control), FLAG-β-arrestin 
2 (WT), FLAG-β-arrestin 2K18R, K107R, K108R, K207R, K296R or 
FLAG-β-arrestin 2K11R, K12R. 24 hr after transfection, cells 
were treated with 1 mM carbachol for 1 hr. Internalization 
was determined in whole cells (receptors/cell) as described 
in methods. All constructs were able to mediate agonist-pro-
moted internalization. Data are expressed as percent of 
[3H]-NMS bound compared to untreated control and pre-
sented as mean ± standard deviation from three independent 
experiments with duplicate data points. Statistical analysis 
was performed using a repeated measures ANOVA with 
Bonferroni post test; * indicates p ≤  0.05 (compared to 
untreated, no β-arrestin control), ns indicates not significant. 
Total receptor expressed in the presence of all four β-arres-
tin constructs was between 5 and 6 × 105 receptor/cell.
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β-arrestin 2K18R, K107R, K108R, K207R, K296Rdemonstrates impaired  agonist-promoted co-localiztion with M2 mAChR in MEF  KO1/2 Figure 9
β-arrestin 2K18R, K107R, K108R, K207R, K296Rdemonstrates 
impaired agonist-promoted co-localiztion with M2 
mAChR in MEF KO1/2. MEF KO1/2 cells were trans-
fected with HA-M2 mAChRs (green) and either wild-type 
FLAG-β-arrestin 2, FLAG-β-arrestin 2K18R, K107R, K108R, K207R, 
K296R or FLAG-β-arrestin 2K11R, K12R (red). 24 hr after trans-
fection, cells were treated with 1 mM carbachol for 30 min. 
Cells were fixed, probed, and imaged as described in meth-
ods. Wild-type and β-arrestin 2K11R, K12R demonstrate co-
localization with the M2 mAChR which is significantly dimin-
ished with β-arrestin 2K18R, K107R, K108R, K207R, K296R. Image 
shown is representative of two independent experiments.
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Co-localization of wild-type and β-arrestin 2K11R, K12R with
the M2 mAChR, observed after 30 min of agonist treat-
ment is absent with β-arrestin 2K18R, K107R, K108R, K207R, K296R
which may indicate a disrupted or impaired interaction
between this β-arrestin mutant and the M2 mAChR. β-
arrestin 2K18R, K107R, K108R, K207R, K296R was also shown to dis-
rupt the co-localization of the M2 mAChR and the lyso-
somal marker LAMP-1 confirming our observation that β-
arrestin 2K18R, K107R, K108R, K207R, K296R does not mediate the
agonist-promoted degradation of the M2 mAChR. Surpris-
ingly, no co-localization of M1 mAChR was observed with
any of the three β-arrestin constructs. Time points from 1
min to 12 hrs of carbachol treatment were performed to
attempt to image co-localization between the M1 mAChR
and the β-arrestins (data not shown). This observation
seems to indicate that the role of β-arrestin in M1 mAChR
down-regulation may involve a transient interaction
between β-arrestin and the receptor which fates the recep-
tor toward degradation.
Our observations of M2 mAChR trafficking are different
from the results of work with the Class A β2 AR [17] which
suggests that ubiquitination of β-arrestin is required for
receptor internalization and that ubiquitination of the
receptor itself is required for receptor degradation. Our
data indicate that, for the M1 mAChR, the ubiquitination
state of β-arrestin appears to have a role in the level of con-
stitutive (agonist-independent) down-regulation and for
the M2 mAChR the ubiquitination state of β-arrestin has a
direct role in the agonist-promoted down-regulation of
the receptor. Of the seven lysine residues we examined, at
least one (or more) of the group 18, 107, 108, 207 and
296 are required for this M2 mAChR down-regulation. We
also observed that M2 mAChR internalization was inde-
pendent of β-arrestin ubiquitination at these same lysine
residues that have been shown to interfere with the asso-
ciation of β-arrestin with other Class B receptors [22]. The
possibility that other lysine residues than those we exam-
ined are ubiquitinated in order to internalize the receptor
would preserve the role for β-arrestin in receptor internal-
ization. The absence of down-regulation of M2 mAChRs
with  β-arrestin 2K18R, K107R, K108R, K207R, K296R however,
clearly indicates a direct role for the ubiquitination of β-
arrestin in receptor down-regulation.
Conclusion
We conclude that agonist-promoted down-regulation of
both M1 and M2 mAChRs is β-arrestin-dependent. We fur-
ther conclude that this down-regulation is specifically
modulated by the ubiquitination state of β-arrestin and
that this β-arrestin ubiquitination differentially targets the
receptor subtypes for degradation in lysosomes. Signifi-
cantly, where it has been suggested that Class A GPCR
down-regulation proceeds primarily via receptor ubiquiti-
nation, these data indicate that the ubiquitination state of
β-arrestin 2 has an essential role in the differential target-
ing the M1  and M2  mAChR toward down-regulation.
Future studies will examine the role of receptor ubiquiti-
nation in M1 and M2 mAChR down-regulation. Specifi-
cally, we will examine whether expression of wild type vs
the β-arrestin 2K18R, K107R, K108R, K207R, K296R mutant differen-
tially affects M1 and M2 mAChR ubiquitination and subse-
quent down-regulation.
Methods
Reagents
[3H]-N-methylscopolamine -(81–84 Ci/mmol) and [3H]-
L-quinuclidinyl benzilate- (43 Ci/mmol) were purchased
from Amersham Corporation (Buckinghamshire, Eng-
land). LipofectAMINE 2000 and Protein A agarose were
purchased from Invitrogen (Carlsbad, CA). Halt protease
inhibitor and BCA protein assay kit were purchased from
Pierce (Rockford, Il). Atropine, N-ethyl maleimide, car-
bamyl choline chloride, -anti-FLAG polyclonal antibody
(F7425); polyclonal anti-LAMP1 antibody (L1418) and
all other chemicals were purchased from Sigma Aldrich
(St. Louis, MO). Anti-FLAG monoclonal antibody (200–
472) was purchased from Stratagene (La Jolla, CA). Mon-
oclonal anti-HA antibody (MMS101R) was purchased
from Covance (Berkeley, CA). Polyclonal anti-HA anti-
body (71–5500) was purchased from Zymed (Carlsbad,
β-arrestin 2K18R, K107R, K108R, K207R, K296Rdemonstrates no co- localization with M1 mAChR in MEF KO1/2 Figure 10
β-arrestin 2K18R, K107R, K108R, K207R, K296Rdemonstrates 
no co-localization with M1 mAChR in MEF KO1/2. 
MEF KO1/2 cells were transfected with eGFP-M1 (A) 
mAChRs (green) and either wild-type FLAG-β-arrestin 2, 
FLAG-β-arrestin 2K18R, K107R, K108R, K207R, K296R or FLAG-β-
arrestin 2K11R, K12R (red). 24 hr after transfection, cells were 
treated with 1 mM carbachol for 30 min. Cells were fixed, 
probed, and imaged as described in methods. None of the β-
arrestin constructs demonstrate co-localization with the M1 
mAChR. Image shown is representative of two independent 
experiments.
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CA). Monoclonal anti-Ub antibody P4D1 (sc 8017) was
purchased from Santa Cruz Biotech (Santa Cruz, CA).
Alexa 594 goat anti-mouse, Alexa 488 goat anti-Rabbit
and Texas red goat anti-mouse (115-075-003) were pur-
chased from Molecular Probes (Eugene, OR). FITC goat
anti-rabbit (AP132F) was purchased from Chemicon
(Temecula, CA). -HRP-conjugated secondary antibodies
were purchased from Bio-Rad Laboratories (Hercules,
CA). Prolong Gold Antifade (P36930) was purchased
from Jackson Immuno Research (West Grove, PA.). pIRE-
SeGFP were purchased from Clontech (Palo Alto CA).
Expression constructs and cell lines
Expression constructs and cell lines were generously pro-
vided by the following: MEF wild-type cells, β-arrestin 1
and 2 double knockout cells, FLAG-tagged β-arrestin 1
and 2, YFP-β-arrestin-2-Ub, β-arrestin 2K11R, K12R, and β-
arrestin 2K18R, K107R, K108R, K207R, K296R (pcDNA3.1 FLAG β-
arrestin 1 or 2, pEYFP β-Arr-Ub, pcDNA3.1 FLAG β-arres-
tin 2K11R, K12R, and pcDNA3.1 FLAG β-arrestin 2K18R, K107R,
K108R, K207R, K296R) by Dr. Robert Lefkowitz (Duke Univer-
sity Medical Center, Durham, NC); HA tagged human M2
mAChR (pRK HA M2 mAChR) by Dr. Audrey Claing (Uni-
versity of Montreal, Montreal Canada); eGFP tagged M1
mAChR (pCEP4eGFP M1 mAChR by Dr. Brigitte Ilien
(University of Strasbourg, Strasbourg, France).
Cell culture and transient transfection
Mouse embryonic fibroblast (MEF) cells (wild-type and
knockouts) were maintained in Dulbecco's Modified
Eagle's Medium (DMEM). Media was supplemented with
10% fetal bovine serum (FBS), 100 IU/mL penicillin, and
100  μg/mL streptomycin. All cells were maintained at
37°C with 5% CO2. At 24 hr prior to transfection, cells
were plated at 7.5 × 104 cells/well (12-well plate), 1.5 ×
105cells/well (6-well plate) and 2 × 106 cells/dish (100
mm dish). Cells were transfected using LipofectAMINE
2000 according to the manufacturer's protocol with 1.6, 5
β-arrestin 2K18R, K107R, K108R, K207R, K296Rdisrupts the co-localization of M2 mAChR and LAMP-1 in MEF KO1/2 Figure 11
β-arrestin 2K18R, K107R, K108R, K207R, K296Rdisrupts the co-localization of M2 mAChR and LAMP-1 in MEF KO1/2. MEF 
KO1/2 cells were transfected with HA-M2 mAChR and either wild-type FLAG-β-arrestin 2, FLAG-β-arrestin 2K18R, K107R, K108R, 
K207R, K296R or FLAG-β-arrestin 2K11R, K12R. 24 hr after transfection, cells were treated with 1 mM carbachol for 6 hr. Cells were 
fixed, probed, and imaged as described in methods. β-arrestin 2K18R, K107R, K108R, K207R, K296R disrupts the co-localization of M2 
mAChR and LAMP-1 compared to wild-type and β-arrestin 2K11R, K12R. Image shown is representative of three independent 
experiments.
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or 25 μg total DNA per well/plate on a 12-well plate, 6-
well plate and 100 mm dish, respectively. Transfection
efficiencies of 40 – 60% were routinely obtained [deter-
mined by including 10% of total DNA as eGFP construct
(pIRESeGFP) and visualizing transfected cells using an
Olympus 1X71 fluorescent microscope].
Crude membrane preparation
Two wells of a 6-well plate were rinsed twice with ice cold
PBS and cells were scraped in 50 mM sodium phosphate
pH 7.0, pooled and homogenized with 20 strokes
through a Dounce homogenizer. Homogenate was spun
at 10,000 rpm for 20 min at 4°C in a Sorvall Mach 1.6R
fixed angle rotor. Pellet was resuspended in 50 mM
sodium phosphate pH 7.0 and spun again. Pellet was
resuspended in 0.55 mL 50 mM sodium phosphate pH
7.0 and used for protein assay and radioligand binding.
Immunoprecipitation
At 24 hr post transfection, cells were lysed by sonication
in HEPES lysis buffer (50 mM HEPES, pH 7.5, 1% Triton
X-100, 10% glycerol, 10 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 50 mM NaF, 10 mM N-ethyl maleimide, 1 μg/mL
each leupeptin, aprotinin, and pepstatin A). Next, 500 μg
(BCA) of lysate was precleared using Protein-A agarose
beads for 4 hr at 4°C followed by incubation with 5 μg of
monoclonal anti-FLAG antibody at 4°C overnight. The
immunocomplex was incubated for 4 hr with 100 μL Pro-
tein-A beads (50% slurry) at 4°C with rotation. Beads
were washed 3 × 500 μL in the same buffer and resus-
pended in 30 μl of Laemmli buffer and boiled for 5–10
min. The immunocomplex was resolved on a 10%
sodium dodecyl sulfate polyacrylamide gel electrophore-
sis (SDS-PAGE) gradient gel.
Immunoblotting
Lysates were prepared as described above and 10 – 20 μg
total protein was run on a 10% SDS-PAGE gel. Samples
from immunoprecipitation or for direct immnuoblotting
were transferred to nitrocellulose membranes, blocked
with 5% powdered nonfat milk in Tris Buffered Saline,
0.1% Tween 20 (TBST) and probed with antibody as indi-
cated. Immunoreactive bands were visualized with a Fuji
imaging system using enhanced chemiluminescence after
adding HRP conjugated secondary antibody.
Radioligand binding
Internalization
Internalization was determined by measuring the binding
of – the membrane-impermeable muscarinic antagonist
[3H]-N-methylscopolamine (NMS) to intact cells. Briefly,
24–42 hr after transfection, MEF cells were treated or not
treated with 1 mM carbachol for 30 min or 1 h at 37°C.
Cultures were washed 3 × 1 mL with serum free media and
incubated with 100 nM – [3H]-NMS in 1 mL PBS for 30
min at 37°C or 4 hr at 4°C. Nonspecific binding was
determined as the bound radioactivity in the presence of
1 μM atropine. Labeled cells were washed 3 × 1 mL with
ice-cold PBS, solubilized in 0.5 mL 1% Triton-X-100, and
combined with 3.5 mL scintillation fluid followed by
measurement of radioactivity. Cpm were converted to
receptors per well which were then corrected to receptors
per cell by dividing by cells/well. Cells were counted using
a standard haemocytometer. Receptor internalization is
defined as percent of surface M2 mAChR not accessible to
[3H]-NMS at each time relative to untreated or control
cells.
Down-regulation
Down-regulation was determined by measuring the bind-
ing of the membrane permeable muscarinic antagonist
[3H]-L-quinuclidinyl benzilate (QNB). Crude membranes
(100 μL) were incubated with 30 nM [3H]-QNB in a total
volume of 1 mL 50 mM sodium phosphate pH 7.0 for 2
hr at 25°C. Nonspecific binding was determined as the
bound radioactivity in the presence of 1 μM atropine.
Membranes were harvested on glass fiber filters using a
Brandel cell harvester (Gaithersburg, MD) and washed 3 ×
2 mL with ice cold 50 mM sodium phosphate pH 7.0. Fil-
ter discs were combined with 3.5 mL scintillation fluid
followed by measurement of radioactivity.
Cpm per tube was converted to fmoles receptor, which
was then corrected to mg of total protein per tube. Percent
down-regulation was determined as percent of sites
remaining compared to untreated control membranes.
Indirect immunofluorescence
LAMP-1:M2 mAChR co-localization
Cells were fixed in 4% formaldehyde in PBS for 5 minutes,
and rinsed with 10% fetal bovine serum and 0.02% azide
in PBS (PBS/serum). Fixed cells were incubated with pri-
mary antibodies (1:1000 anti-LAMP1 and 1:500 anti-HA
MAb) diluted in PBS/serum containing 0.2% saponin for
45 minutes, and then washed with PBS/serum (3 × 5
min.). The cells were then incubated with fluorescently
labeled secondary antibodies (1:800 Alexa 488 goat anti-
rabbit and Alexa 594 goat anti-mouse) in PBS-serum and
0.2% saponin for 45 minutes, washed with PBS/serum (3
× 5 min.) and once with PBS, and mounted on glass slides
in prolong gold antifade.
FLAG- -Arrestin 2:HA-M2 mAChR or eGFP-M1 mAChR co-
localization
Cells were fixed in 4% formaldehyde in PBS for 5 minutes.
Fixed cells were permeabilized for 5 minutes with 0.1%
triton in PBS and washed 3 × with PBS and blocked in rab-
bit pre-immune sera (1:200 in PBS). Fixed cells were incu-
bated with primary antibodies (1:500 anti HA PAb or
1:800 anti FLAG MAb) rinsed 3 × with PBS ad incubatedPublish with BioMed Central    and   every 
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with fluorescent secondary antibodies (1:1000 FITC goat
anti-rabbit or 1:1000 Texas red goat anti-mouse). Cover-
slips were mounted on slides in prolong gold antifade.
Images were acquired using an Olympus 1X71 inverted
fluoresecent microscope equipped with a 60x oil immer-
sion objective. Images were obtained with Olympus
Image Manager (Center Valley, PA).
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